
Individuals with cardiac implantable electronic devices have a higher risk of tricuspid regurgitation (TR), according to a study presented at AHA 2024.
In this study, investigators used the California’s Department of Health Care Access and Information databases to analyze 16,893,314 participants (56,095,327 person years). The primary end points of interest were defined as the development of TR and tricuspid intervention.
Overall, there were 11,234 instances of TR. The findings showed that CIED implantation was correlated with a 13-fold higher risk of incident TR. Subsequent to adjusting for age, sex, race and ethnicity, income, heart failure, atrial fibrillation, hypertension, pulmonary hypertension, coronary artery disease, chronic kidney disease, hyperlipidemia, diabetes mellitus, chronic obstructive pulmonary disease, asthma, obstructive sleep apnea, alcohol use, cocaine use, methamphetamine use, opiate use, and tobacco use, the results showed that patients with a CIED exhibited a 15% higher risk of TR.